Get started
Author

Carlos Torrado

Observed name: C. Torrado Martin
ORCID: 0000-0001-7063-1156
Observed ORCID: 0000-0001-7063-1156
OpenAlex ID: A5065557782
Palliative care in Africa: a scoping review from 2005–16
2017 · John Y Rhee, Eduardo Garralda, et al. · The Lancet Oncology · 102
Synthetic lethal strategies for the development of cancer therapeutics
2024 · Natalie Y. L. Ngoi, David Gallo, et al. · Nature Reviews Clinical Oncology · 79
USP1 inhibition: A journey from target discovery to clinical translation
2025 · Carlos Torrado, Nicholas W. Ashton, et al. · Pharmacology & Therapeutics · 33
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
2024 · Julia Martínez-Pérez, Carlos Torrado, et al. · International Journal of Molecular Sciences · 19
Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine
2024 · Jibran Ahmed, Carlos Torrado, et al. · JCO Precision Oncology · 16
Publications on Palliative Care Development Can Be Used as an Indicator of Palliative Care Development in Africa
2017 · John Y. Rhee, Eduardo Garralda, et al. · Journal of Palliative Medicine · 15
A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives
2024 · Carlos Diego Holanda Lopes, Camila Braganca Xavier, et al. · Journal of Immunotherapy and Precision Oncology · 11
Drugging the DNA damage response in the clinic: going beyond PARP
2025 · Carlos Torrado, Alvaro Gonzalez-Ortiz, et al. · Expert Review of Anticancer Therapy · 8
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma
2025 · Natalie Y. L. Ngoi, Ian M. Silverman, et al. · npj Precision Oncology · 6
PDF
Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy
2024 · Carlos Torrado, Mehmet A. Baysal, et al. · Frontiers in Immunology · 4
Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report
2024 · Carlos Torrado, Jamie Feng, et al. · JTO Clinical and Research Reports · 4
PDF
Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature
2023 · Carlos Torrado, Melisa Camaño, et al. · Cancers · 4
PDF
Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases
2025 · Carlos Torrado, Elise Nassif Haddad, et al. · Journal of Immunotherapy and Precision Oncology · 3
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies
2025 · Jibran Ahmed, Anne Knisely, et al. · The Oncologist · 3
Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications
2024 · Carlos Torrado, Ruth Plummer, et al. · JCO Precision Oncology · 3
PDF
Spatial RNA–protein profiling of antibody–drug conjugate (ADC) targets in leiomyosarcoma (LMS).
2026 · Carlos Torrado, J. Andrew Livingston, et al. · Journal of Clinical Oncology · 1
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity
2026 · Carlos Torrado, Clark R Andersen, et al. · The Oncologist · 1
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
2026 · Carlos Torrado, Anthony P. Conley · Expert Opinion on Investigational Drugs
Abstract B035: A Phase 2 Platform Trial Integrated with Patient Digital Twins to Prioritize and Refine Therapies for Sarcomas: The RAPID Study
2026 · Carlos Torrado, Kevin A. Murgas, et al. · Cancer Research
Atypical radiologic response patterns in patients treated on immunotherapy clinical trials: A retrospective lesion-level analysis.
2026 · Carlos Torrado, Jacopo Venturini, et al. · Journal of Clinical Oncology
PDF
Real-world outcomes of doxorubicin plus trabectedin (D+T) in leiomyosarcoma (LMS).
2026 · Stephanie Soewito, Nassar El Assaad, et al. · Journal of Clinical Oncology
From eligibility to enrollment: Evaluating barriers to clinical trial participation for leiomyosarcoma (LMS) at MD Anderson Cancer Center (MDACC).
2026 · Nisha Bhatti, Ravin Ratan, et al. · Journal of Clinical Oncology
Immune checkpoint blockade (ICB) in advanced/metastatic leiomyosarcoma (LMS): Real-world cohort from MD Anderson.
2026 · Nassar El Assaad, Michael S. Nakazawa, et al. · Journal of Clinical Oncology
PDF
Secondary genomic alterations and clinical outcomes in myxoid liposarcoma: A multi-institutional analysis.
2026 · Daniel Reinhorn, George Z. Li, et al. · Journal of Clinical Oncology
Phase I trial of combination gemcitabine (gem) and nab-sirolimus (nab-S) in advanced leiomyosarcomas (LMS) or advanced soft-tissue sarcomas (STS) with TSC1/2 alterations: Preliminary results.
2026 · Elise F. Nassif Haddad, Heather Y. Lin, et al. · Journal of Clinical Oncology
Works count: 32
Citation count: 312
H-index: 8
I10-index: 7
Year
Topic
Type